Source link : https://www.newshealth.biz/health-news/why-alzheimers-drug-approval-delay-3-billion-in-dmd-gene-therapy-adhd-prevalence/
Why is donanemab, an investigational anti-amyloid agent for early Alzheimer’s disease, facing an approval delay? (The Guardian) Early use of erenumab (Aimovig) showed sustained efficacy compared with oral migraine preventives in treatment-resistant episodic migraine. (JAMA Neurology) Net sales for eteplirsen (Exondys 51), golodirsen (Vyondys 53), and casimersen (Amondys 45) — three genetically targeted therapies for […]
Author : News Health
Publish date : 2024-03-26 10:16:49
Copyright for syndicated content belongs to the linked Source.
Categories